

# Mark Bustoros

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4622917/publications.pdf>

Version: 2024-02-01

39  
papers

1,238  
citations

516215

16  
h-index

395343

33  
g-index

39  
all docs

39  
docs citations

39  
times ranked

2135  
citing authors

#	ARTICLE	IF	CITATIONS
1	Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. <i>Nature Cancer</i> , 2020, 1, 493-506.	5.7	209
2	Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma. <i>Nature Communications</i> , 2018, 9, 1691.	5.8	153
3	Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. <i>Journal of Clinical Oncology</i> , 2020, 38, 2380-2389.	0.8	110
4	Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies. <i>Journal of Clinical Oncology</i> , 2020, 38, 1198-1208.	0.8	103
5	Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. <i>Nature Communications</i> , 2020, 11, 2996.	5.8	98
6	Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression. <i>Journal of Clinical Investigation</i> , 2018, 128, 2487-2499.	3.9	80
7	Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2019, 37, 1403-1411.	0.8	65
8	Genome instability in multiple myeloma. <i>Leukemia</i> , 2020, 34, 2887-2897.	3.3	63
9	Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma. <i>Blood</i> , 2018, 132, 804-804.	0.6	42
10	Patient-Specific Screening Using High-Grade Glioma Explants to Determine Potential Radiosensitization by a TGF- $\beta$ 2 Small Molecule Inhibitor. <i>Neoplasia</i> , 2016, 18, 795-805.	2.3	35
11	Traumatic brain injury and subsequent glioblastoma development: Review of the literature and case reports. , 2016, 7, 78.		31
12	Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients. <i>Blood</i> , 2018, 132, 2608-2612.	0.6	29
13	Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study. <i>Lancet Haematology</i> , 2022, 9, e340-e349.	2.2	27
14	Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration. <i>Clinical Cancer Research</i> , 2021, 27, 5195-5212.	3.2	26
15	Advancements in Nanomedicine for Multiple Myeloma. <i>Trends in Molecular Medicine</i> , 2018, 24, 560-574.	3.5	23
16	Established and Novel Prognostic Biomarkers in Multiple Myeloma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 548-560.	1.8	21
17	Profiling of circulating exosomal miRNAs in patients with Waldenström Macroglobulinemia. <i>PLoS ONE</i> , 2018, 13, e0204589.	1.1	17
18	A Rare Case of Composite Dural Extranodal Marginal Zone Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <i>Frontiers in Neurology</i> , 2018, 9, 267.	1.1	16

#	ARTICLE	IF	CITATIONS
19	Placental extracellular vesicles-associated microRNA-519c mediates endotoxin adaptation in pregnancy. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 225, 681.e1-681.e20.	0.7	15
20	Established and Novel Prognostic Biomarkers in Multiple Myeloma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 548-560.	1.8	12
21	Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group. <i>American Journal of Hematology</i> , 2019, 94, E146-E149.	2.0	11
22	Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes. <i>Nature Communications</i> , 2022, 13, .	5.8	11
23	Adult Primary Spinal Epidural Extraosseous Ewing's Sarcoma: A Case Report and Review of the Literature. <i>Case Reports in Neurological Medicine</i> , 2016, 2016, 1-8.	0.3	9
24	The Role of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Multiple Myeloma: Immunomodulator Maintenance Post Autologous Stem Cell Transplant (ASCT) Predicts Better Outcome. <i>Blood</i> , 2018, 132, 749-749.	0.6	6
25	Pregnancy Outcomes, Risk Factors, and Gestational Cell Count Trends in Pregnant Women with Essential Thrombocythemia and Polycythemia Vera. <i>Blood</i> , 2019, 134, 4172-4172.	0.6	6
26	A Phase II Study of Daratumumab in Patients with High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma: First Report of Efficacy and Safety. <i>Blood</i> , 2019, 134, 1898-1898.	0.6	6
27	An Overview of Selected Rare B-Cell Lymphoproliferative Disorders: Imaging, Histopathologic, and Clinical Features. <i>Cancers</i> , 2021, 13, 5853.	1.7	4
28	High Prevalence of Monoclonal Gammopathy in a Population at Risk: The First Results of the Promise Study. <i>Blood</i> , 2021, 138, 152-152.	0.6	3
29	Single-Cell RNA-Sequencing Identifies Immune Biomarkers of Response to Immunotherapy in Patients with High-Risk Smoldering Myeloma. <i>Blood</i> , 2021, 138, 330-330.	0.6	2
30	Bone marrow niche in multiple myeloma and its precursor states. <i>HemaSphere</i> , 2019, 3, 121-123.	1.2	1
31	The PROMISE Study: A Nationwide Project for Predicting the Progression of Developing Myeloma in a High-Risk Screened Population. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e310.	0.2	1
32	Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression.. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e5-e6.	0.2	1
33	Single-Cell RNA Sequencing Reveals Compromised Immune Microenvironment in Precursor Stages of Multiple Myeloma. <i>Blood</i> , 2018, 132, 2603-2603.	0.6	1
34	Regular Aspirin Use and Mortality in Multiple Myeloma Patients. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, , cebp.EPI-21-0946-E.2021.	1.1	1
35	Reply to F.D. Leonard. <i>Journal of Clinical Oncology</i> , 2019, 37, 2701-2702.	0.8	0
36	Progression risk stratification of Asymptomatic Waldenström Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e38-e39.	0.2	0

#	ARTICLE	IF	CITATIONS
37	Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e27.	0.2	0
38	Genomic Profiling of Smoldering Multiple Myeloma Classifies Molecular Groups with Distinct Pathogenic Phenotypes and Clinical Outcomes. <i>Blood</i> , 2021, 138, 723-723.	0.6	0
39	A Next Generation Liquid Biopsy Approach for Multiple Myeloma. <i>Blood</i> , 2020, 136, 33-33.	0.6	0